NCT00603031

Effect of GLP-1 and GIP on Insulin Secretion in Type-1 Diabetes Mellitus

Effect of GLP-1 and GIP on the Maximal Insulin Secretory Capacity in Type-1 Diabetes Mellitus

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: Hvidovre University Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

study hypothesis: treatment with GLP-1 and/or GIP is able to potentiate the maximal stimulated insulin secretion even in c-peptide negative type-1 diabetic patients classified as having no residual beta cell function left.

Conditions

• Type-1 Diabetes Mellitus

Interventions

Type	Name	Description
OTHER	glucagon like peptide -1	continuous infusion 1,2 pmol pr. kg pr minute at 120 minutes
OTHER	NaCl	infusion with NaCl for 120 minutes as placebo-arm
OTHER	glucose dependent insulinotropic polypeptide	continuous infusion with GIP-1 (3,6pmol/kg/min) at 120 minutes.

Timeline

• Start date: 2008-01-01
• Primary completion: 2008-06-01
• Completion: 2008-06-01
• First posted: 2008-01-28
• Last updated: 2011-01-21

Locations

1 site across 1 country: Denmark